Homoeopathy as an Adjuvant to Standard Care in Moderate and Severe Cases of COVID-19: A Single-Blind, Randomized, Placebo-Controlled Study

  SFX Search  Buy Article Permissions and Reprints Abstract

Objectives This study aimed to evaluate whether individualized homeopathic medicines have a greater adjunctive effect than adjunctive placebos in the treatment of moderate and severe cases of coronavirus disease 2019 (COVID-19).

Methods The study was a randomized, single-blind, prospective, placebo-controlled clinical trial set in the clinical context of standard care.

Intervention Patients of either sex, admitted in a tertiary care hospital, suffering from moderate or severe COVID-19 and above 18 years of age were included. In total, 150 patients were recruited and then randomly divided into two groups to receive either individualized homeopathic medicines or placebos, in addition to the standard treatment of COVID-19.

Outcome Measures The primary outcome was time taken to achieve RT-PCR-confirmed virus clearance for COVID-19. Secondary outcomes were changes in the Clinical Ordinal Outcomes Scale (COOS) of the World Health Organization, the patient-reported MYMOP2 scale, and several biochemical parameters. Parametric data were analyzed using unpaired t-test. Non-parametric data were analyzed using the Wilcoxon signed rank test. Categorical data were analyzed using Chi-square test.

Results In total, 72 participants of the add-on homeopathy (AoH) group showed conversion of RT-PCR status to negative, in an average time of 7.53 ± 4.76 days (mean ± SD), as compared with 11.65 ± 9.54 days in the add-on placebo (AoP) group (p = 0.001). The mean COOS score decreased from 4.26 ± 0.44 to 3.64 ± 1.50 and from 4.3 ± 0.46 to 4.07 ± 1.8 in the AoH and AoP groups respectively (p = 0.130). The mortality rate for the AoH group was 9.7% compared with 17.3% in the AoP group. The MYMOP2 scores between the two groups differed significantly (p = 0.001), in favor of AoH. Inter-group differences in the pre- and post- mean values of C-reactive protein, fibrinogen, total leukocyte count, platelet count and alkaline phosphatase were each found to be statistically significant (p <0.05), favoring AoH; six other biochemical parameters showed no statistically significant differences.

Conclusion The study suggests homeopathy may be an effective adjunct to standard care for treating moderate and severe COVID-19 patients. More rigorous, including double-blinded, studies should be performed to confirm or refute these initial findings.

Keywords moderate to severe COVID-19 - coronavirus infection - homeopathy - integrative care - pandemic - RT-PCR Data Sets

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


Authors' Contributions

Harleen Kaur conceptualized and designed the study, in consultation with Arvind Dayal, the statistician. She drafted the protocol, sought approvals from the concerned committees, executed the study as the Team Leader, and was involved in final compilation and analysis of the data. There were two teams that alternated for duties, with a period of 15 days home quarantine following 15 days COVID duty. Team A was led by Harleen, and Team B was led by Subhash Kaushik. Besides, Subhash was instrumental in effecting homoeopathic prescriptions in treating moderate and severe COVID-19 cases. Sushma Bhatnagar and Anil Khurana played a pivotal role by mentoring the teams for the study, and guiding them from time to time. Naval Kumar Verma provided his clinical acumen on a case-to-case basis, as and when consulted, and also shared a reference compendium of medical literature for quick reference. Khushbu Gautam, Gurpreet Singh and Shweta Singh, and Maneet Parewa, Tania Chatterjee and Syed Ali were the three assisting homoeopathy doctors in Teams A and B, respectively. Arvind Dayal helped in statistical analysis of the huge data generated from the study, along with Harleen, Gurpreet and Shweta. Suraj Pal Singh and Varun Shekhar were instrumental in all study-related coordination with AIIMS' clinical and paramedical staff for execution of the study. All the authors read the draft manuscript and provided their inputs for its refinement or modification. All authors assure the completeness and accuracy of the data and the adherence of the trial to the protocol.


Publication History

Received: 25 February 2022

Accepted: 13 June 2022

Article published online:
28 November 2022

© 2022. Faculty of Homeopathy. This article is published by Thieme.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

留言 (0)

沒有登入
gif